Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document foreign issuer current reports, oncology program updates, financing transactions, governance changes, and liquidity-related disclosures. The company furnishes Form 6-K reports and references Form 20-F reporting status, with exhibits covering financial results, clinical updates for vebreltinib, and corporate developments affecting ongoing operations.
The filing record also covers material agreements, related-party convertible note financing, PIPE share issuance, resale registration obligations, board and committee appointments, proxy materials, and risk disclosures tied to cash resources, collaboration payments, Nasdaq listing compliance, and the company’s capital structure as a Cayman Islands issuer with Class A ordinary shares and warrants.
Apollomics Inc. director Huang Ya-Chi exercised restricted stock units that vested into common equity. On May 17, 2026, 500 Restricted Stock Units vested and were converted into 500 Class A Ordinary Shares at an exercise price of $0.00 per share.
Following this transaction, Huang directly holds 1,000 Class A Ordinary Shares. The RSU grant was previously disclosed, with 500 RSUs vesting on each of February 17, 2026 and May 17, 2026, and an additional 500 RSUs scheduled to vest on each of August 17, 2026 and November 17, 2026.
Apollomics Inc. director Huang Ya-Chi exercised restricted stock units that vested into common equity. On May 17, 2026, 500 Restricted Stock Units vested and were converted into 500 Class A Ordinary Shares at an exercise price of $0.00 per share.
Following this transaction, Huang directly holds 1,000 Class A Ordinary Shares. The RSU grant was previously disclosed, with 500 RSUs vesting on each of February 17, 2026 and May 17, 2026, and an additional 500 RSUs scheduled to vest on each of August 17, 2026 and November 17, 2026.
Apollomics Inc. reported full-year 2025 results showing its first revenue of $8.5M, driven by an upfront payment from the LaunXP licensing deal for vebreltinib in parts of Asia. The company sharply cut operating expenses to $19.8M from $55.7M, reducing its net loss to $10.9M (or $7.57 per diluted share) from $53.9M in 2024.
Cash, cash equivalents, bank deposits and money market funds were $3.3M as of December 31, 2025, down from $9.8M a year earlier, despite raising $4.1M via a PIPE in September 2025. The balance sheet showed a total equity deficit of $3.2M, reflecting accumulated losses. Strategically, Apollomics highlighted global Phase 2 development of its lead c-MET inhibitor vebreltinib, Chinese approvals for vebreltinib and PD-L1 antibody APL-502 in multiple indications, and a 2025 turnaround effort under a new management team with substantial cost reductions and resolution of legacy legal and clinical obligations.
Apollomics Inc. reported full-year 2025 results showing its first revenue of $8.5M, driven by an upfront payment from the LaunXP licensing deal for vebreltinib in parts of Asia. The company sharply cut operating expenses to $19.8M from $55.7M, reducing its net loss to $10.9M (or $7.57 per diluted share) from $53.9M in 2024.
Cash, cash equivalents, bank deposits and money market funds were $3.3M as of December 31, 2025, down from $9.8M a year earlier, despite raising $4.1M via a PIPE in September 2025. The balance sheet showed a total equity deficit of $3.2M, reflecting accumulated losses. Strategically, Apollomics highlighted global Phase 2 development of its lead c-MET inhibitor vebreltinib, Chinese approvals for vebreltinib and PD-L1 antibody APL-502 in multiple indications, and a 2025 turnaround effort under a new management team with substantial cost reductions and resolution of legacy legal and clinical obligations.
Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report showing equity awards and share holdings. The filing lists 1,000 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. These RSUs are scheduled to vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also reports direct ownership of 1,000 Class A Ordinary Shares following the reported positions.
Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report showing equity awards and share holdings. The filing lists 1,000 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. These RSUs are scheduled to vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also reports direct ownership of 1,000 Class A Ordinary Shares following the reported positions.
Apollomics Inc. director Tsai Hsien-Shu reports equity holdings consisting of restricted stock units and common shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.00 per share.
These restricted stock units will vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also lists direct ownership of 1,000 Class A Ordinary Shares following the reported holdings.
Apollomics Inc. director Tsai Hsien-Shu reports equity holdings consisting of restricted stock units and common shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.00 per share.
These restricted stock units will vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also lists direct ownership of 1,000 Class A Ordinary Shares following the reported holdings.
Apollomics Inc. Chief Financial Officer LIN PETER KUAN-HOW reported his equity holdings in an amended Form 3. He holds restricted stock units representing 20,000 Class A Ordinary Shares and 15,900 Class A Ordinary Shares directly. The restricted stock units will vest in two equal installments of 10,000 shares each on June 15, 2026 and September 15, 2026.
Apollomics Inc. Chief Financial Officer LIN PETER KUAN-HOW reported his equity holdings in an amended Form 3. He holds restricted stock units representing 20,000 Class A Ordinary Shares and 15,900 Class A Ordinary Shares directly. The restricted stock units will vest in two equal installments of 10,000 shares each on June 15, 2026 and September 15, 2026.
Apollomics Inc. director and CEO Chen Hung-Wen has updated his reported equity holdings. The filing shows direct ownership of 143,334 Class A Ordinary Shares and indirect ownership of 763,028 Class A Ordinary Shares through King Regent Management Limited, where he is the sole director and shareholder and has voting and dispositive power.
He also holds Restricted Stock Units representing a contingent right to receive 10,000 Class A Ordinary Shares at an exercise price of $0.0000 per share. These RSUs are scheduled to vest in two equal tranches of 5,000 shares on June 15, 2026 and September 15, 2026. Mr. Chen disclaims beneficial ownership of the securities held by King Regent Management Limited except to the extent of his pecuniary interest.
Apollomics Inc. director and CEO Chen Hung-Wen has updated his reported equity holdings. The filing shows direct ownership of 143,334 Class A Ordinary Shares and indirect ownership of 763,028 Class A Ordinary Shares through King Regent Management Limited, where he is the sole director and shareholder and has voting and dispositive power.
He also holds Restricted Stock Units representing a contingent right to receive 10,000 Class A Ordinary Shares at an exercise price of $0.0000 per share. These RSUs are scheduled to vest in two equal tranches of 5,000 shares on June 15, 2026 and September 15, 2026. Mr. Chen disclaims beneficial ownership of the securities held by King Regent Management Limited except to the extent of his pecuniary interest.
Apollomics Inc. director CHU YI-AN reports equity holdings consisting of restricted stock units and related Class A Ordinary Shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.0000 per share.
According to the disclosure, these restricted stock units are scheduled to vest with respect to 500 shares on June 15, 2026 and 500 shares on September 15, 2026. Following this reporting, the position includes 1,000 Class A Ordinary Shares tied to this award, all held as direct ownership.
Apollomics Inc. director CHU YI-AN reports equity holdings consisting of restricted stock units and related Class A Ordinary Shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.0000 per share.
According to the disclosure, these restricted stock units are scheduled to vest with respect to 500 shares on June 15, 2026 and 500 shares on September 15, 2026. Following this reporting, the position includes 1,000 Class A Ordinary Shares tied to this award, all held as direct ownership.
Apollomics Inc. chief operating officer Chen Yi-Kuei filed an amended initial ownership report detailing his equity interests. He directly holds 10,000 Class A Ordinary Shares and 10,000 restricted stock units, each representing a right to one Class A Ordinary Share. The restricted stock units will vest in two equal tranches of 5,000 shares on June 15, 2026 and September 15, 2026. In addition, entities associated with him, including Maxpro Investment Co., Ltd., hold 101,248 Class A Ordinary Shares and warrants linked to 3,823 underlying Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, and he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apollomics Inc. chief operating officer Chen Yi-Kuei filed an amended initial ownership report detailing his equity interests. He directly holds 10,000 Class A Ordinary Shares and 10,000 restricted stock units, each representing a right to one Class A Ordinary Share. The restricted stock units will vest in two equal tranches of 5,000 shares on June 15, 2026 and September 15, 2026. In addition, entities associated with him, including Maxpro Investment Co., Ltd., hold 101,248 Class A Ordinary Shares and warrants linked to 3,823 underlying Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, and he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apollomics Inc. director Huang Ya-Chi has reported current equity holdings in the company. The filing shows direct ownership of 1,500 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share. These restricted stock units are scheduled to vest in three equal installments of 500 shares on May 17, 2026, August 17, 2026 and November 17, 2026. The exercise price for the underlying shares is listed as $0.0000 per share. In addition, Huang Ya-Chi directly holds 500 Class A Ordinary Shares following the reported positions.
Apollomics Inc. director Huang Ya-Chi has reported current equity holdings in the company. The filing shows direct ownership of 1,500 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share. These restricted stock units are scheduled to vest in three equal installments of 500 shares on May 17, 2026, August 17, 2026 and November 17, 2026. The exercise price for the underlying shares is listed as $0.0000 per share. In addition, Huang Ya-Chi directly holds 500 Class A Ordinary Shares following the reported positions.
Apollomics Inc. executive Yi-Kuei (Alex) Chen has reported beneficial ownership of approximately 5.3% of the company’s Class A ordinary shares. The position totals 115,171 shares when including 100 shares held directly, 101,248 shares held through Maxpro Investment Co., Ltd., 3,823 shares issuable from warrants held by Maxpro, and 10,000 restricted stock units granted as compensation.
The filing states that 5,000 RSUs vested on February 17, 2026, with another 5,000 scheduled to vest on May 17, 2026, and that this vesting pushed Chen’s beneficial ownership above the 5% threshold. Chen indicates the shares are held for investment purposes and may be increased or reduced over time, while continuing to act in his role as Chief Operating Officer and director.
Apollomics Inc. executive Yi-Kuei (Alex) Chen has reported beneficial ownership of approximately 5.3% of the company’s Class A ordinary shares. The position totals 115,171 shares when including 100 shares held directly, 101,248 shares held through Maxpro Investment Co., Ltd., 3,823 shares issuable from warrants held by Maxpro, and 10,000 restricted stock units granted as compensation.
The filing states that 5,000 RSUs vested on February 17, 2026, with another 5,000 scheduled to vest on May 17, 2026, and that this vesting pushed Chen’s beneficial ownership above the 5% threshold. Chen indicates the shares are held for investment purposes and may be increased or reduced over time, while continuing to act in his role as Chief Operating Officer and director.